DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Bazinet M, Pantea V, Cebotarescu V. et al.
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Lancet Gastroenterol Hepatol 2017;
2: 877-889
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.